ORLANDO—Elevated BMI is in-dependently associated with higher prostate cancer-specific mortality (PCSM) following radiation therapy and androgen suppression in men with locally advanced prostate cancer.
ORLANDO—Blood levels of C-reactive protein (CRP) independently predict survival in men with metastatic androgen-independent prostate cancer (AIPC), researchers conclude. CRP levels also predict the likelihood that patients will respond to therapy.
Biennial PSA screening decreases the likelihood of being diagnosed with metastatic prostate cancer, but nearly doubles the chance of being diagnosed with prostate cancer of any type, a Swedish sudy found.
The FDA has assigned priority review status to the Biologics License Application for Provenge (sipuleucel-T), an investigational immunotherapy for asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.